Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
32.67
+1.65 (5.32%)
At close: Oct 29, 2025, 4:00 PM EDT
32.73
+0.06 (0.18%)
After-hours: Oct 29, 2025, 7:22 PM EDT
Neurogene Revenue
In the year 2024, Neurogene had annual revenue of $925.00K.
Revenue (ttm)
$925.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
107
Market Cap
466.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 925.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNGNE News
- 20 days ago - Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025 - Business Wire
- 21 days ago - Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference - Business Wire
- 26 days ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire
- 3 months ago - What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga
- 4 months ago - Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - Business Wire
- 5 months ago - Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV - Business Wire
- 6 months ago - Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire